Biotech and Pharmaceuticals · global
Fake Petition Cannot Prop Up High Drug Prices: Foreign Drugmaker Crosses the Line Under China’s Centralized Procurement Pressure
A physician petition alleged to have been forged has once again exposed the gray areas in China’s drug price negotiations; as price-cutting mechanisms press closer to profit floors, compliance risks are also shifting from the sales end to the scene of policy lobbying.
The most sensitive part of drug price reform is often not a table of percentage cuts, but who can claim to represent patients and clinical needs. Fierce Pharma reported that a foreign drugmaker was found to be suspected of forging physician petition documents in an attempt to avoid China’s price-cutting mechanism; if the allegations are true, this is not only a compliance failure by a single company, but also reflects the tense position multinational pharmaceutical companies face in the Chinese market under price compression.
The public details provided in the report are limited, and it has not yet clearly stated the name of the company involved, the drug product, how the petition documents were produced, or what penalties Chinese regulators may subsequently impose. What can be confirmed is that the core of the incident is not a dispute over the drug’s efficacy or safety, but whether a company packaged commercial demands as false clinical opinions in order to influence the application of drug pricing policy.
In recent years, China has continued to promote centralized volume-based procurement and medical insurance negotiations, with the aim of using massive purchasing volume in exchange for lower drug prices, reducing the burden on medical insurance and patients. For drugmakers, entering such systems may mean substantial price reductions, but may also bring more stable market volume; refusing or circumventing them may preserve short-term unit prices, but could mean losing broader access opportunities.
Physician opinions carry special weight in this system. The clinical side does indeed best understand whether alternative drugs are sufficient and whether specific patient groups need original drugs or particular dosage forms; but precisely because of this, if physician petitions are manipulated by companies, language that should belong to professional judgment becomes a prop in price negotiations. If such a practice is established, the damage is not only to regulatory trust, but also to the clinical voices that genuinely need to be heard.
**Background Context**
Over the past decade-plus, China’s pharmaceutical market has repeatedly seen compliance storms involving foreign drugmakers, from commercial bribery and academic conference expenses to investigations into medical insurance and sales practices, as regulatory standards have gradually tightened. If this incident is related to price avoidance, it shows that risks are no longer concentrated only among medical representatives and hospital procurement, but have also extended to how companies participate in policy procedures and how they prove that the clinical exceptions they propose have a genuine basis.
For patients, low drug prices do not necessarily equal optimal accessibility; if excessive price cuts lead to supply disruptions, product withdrawals, or insufficient alternatives, they may likewise harm treatment choices. Therefore, the system needs to accommodate reasonable clinical exceptions. But such exceptions must be built on transparent data, verifiable physician opinions, and clear procedures, rather than companies using false documents as a substitute for public discussion.
Because currently available information remains limited, it is still too early to draw conclusions about the legal responsibility and market impact of this incident. The clearer question is this: when China’s drug price reform puts commercial profits, medical insurance spending, and clinical needs at the same negotiating table, multinational pharmaceutical companies that want to preserve their pricing positions must prove to a higher standard that what they are putting forward are medical reasons, not a price defense line disguised as medical reasons.